At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition Sagar Lonial, MD, from Emory University Winship Cancer Institute, Atlanta, GA, summarises data on emerging treatment options for patients with multiple myeloma. In newly diagnosed patients, highlights include results from IFM/DFCI 2009, a phase 3 clinical trial investigating autologous transplantation; IFM 2013-04, a phase 3 clinical trial of bortezomib, thalidomide and dexamethasone (VTD) versus bortezomib, cyclophosphamide and dexamethasone (VCD); and SWOG S0777, a phase 3 clinical trial of bortezomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone. In relapsed/refractory patients, promising results were observed in trials of new daratumumab-…
Author: admin
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Sagar Lonial, MD, from Emory University Winship Cancer Institute, Atlanta, GA, discusses the final analysis of overall survival from Panorama 1, a phase 3 clinical trial that evaluated panobinostat, a histone deacetylase inhibitor, plus bortezomib, a proteasome inhibitor, and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma.
Sagar Lonial, MD from Emory University Winship Cancer Institute, Atlanta, GA gives an overview of the ELOQUENT-2 clinical trial of lenalidomide/dexamethasone with/without elotuzumab in patients with relapsed/refractory multiple myeloma (MM). In previous trials, the combination was very active with over 80% response rate. This Phase III trial led to the approval of the elotuzumab in the USA, and demonstrated a 30% improvement in duration of remission, a higher overall response, and the combination also showed activity in high-risk MM patients, in particular the ones with 17p and (4;14) translocation. These results were presented at the American Society of Hematology (ASH)…
A biosimilar can be defined as a biological product that demonstrates no clinically meaningful differences to an approved biological product. At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Bernard M Y Cheung, MA, MB BChir (Cantab), PhD (Cantab), MRCP (UK), FRCP (Edin), FRCP (Lond), FCP, FHKCP, FHKAM (Medicine), from The University of Hong Kong, Hong Kong, reviews the efficacy and safety of biosimilars, including the concerns and approval process associated with their use. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Claire Harrison of the Guy’s and St. Thomas Hospital in London, UK, talks about how in the UK, clinicians have used the Obstetrics Surveillance System (UKOSS) to collect information on pregnant women with certain conditions, including MPNs. This as served a variety of purposes, it has raised awareness in among Obstetricians and Gynaecologists, and it showed that 70% of pregnancies with MPN are successful without risk for the mother and baby. However, this survey also showed an increased risk of early miscarriage and late pregnancy events (for example, pre-eclampsia, small-for-dates babies, early deliveries, and babies with low Apgar scores). Dr…
Claire Harrison, MD of the Guy’s and St. Thomas Hospital in London, UK, talks about the molecular architecture of myeloproliferative neoplasms (MPN), it’s implication for diagnosis and response to treatment and data supporting this presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. Dr Harrison discusses the database created by the Florence group (Alessandro Vannucchi) and Mayo Clinic (Ayalew Tefferi), which has shown that a significant proportion of polycythemia vera and essential thrombocythemia (ET) have additional mutations that might impact on prognosis. Two groups (Andreas Reiter & Animesh Pardanani, and the Mayo Clinic group) also…
Claire Harrison, MD of the Guy’s and St. Thomas Hospital in London, UK, talks about panobinostat (LBH589), commonly used for the treatment of multiple myeloma, which is now being assessed in myelofibrosis (MF). Panobinostat in combination with ruxolitinib, has been shown to be efficacious and safe for the treatment of myelofibrosis. Other important markers also demonstrated the promising effects of this combinations, such as a 35% reduction in spleen volume and early delivery of changes in bone marrow morphology. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL.
Claire Harrison, MD of the Guy’s and St. Thomas Hospital in London, UK, gives an overview of the latest results of the COMFORT-II clinical trial. This is a Phase 3 trial comparing the efficacy and safety of ruxolitinib in patients with myelofibrosis (MF). At the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL, it was shown that after 5 years of the study 50 patients continued receiving ruxolitinib, the spleen response rate plateaued at approx. 50% and there was a 33% prolongation of survival for patients who received ruxolitinib, which increases to 56% when using the rank…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Janice Tsang, MBBS, MRCP(UK), FRCP(Edin), FHKCP, FHKAM (Medicine), from The University of Hong Kong, Hong Kong, explains the clinical relevance of promising molecular targets, including alterations affecting the ESR1 gene and the PI3K signalling pathway, in the development of targeted therapies for patients with metastatic breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Since the approval of the first antibody-drug conjugate or ADC, now more than 15 years ago, scientists and researchers have sent more than 50 ADCs to be clinically evaluated in ongoing clinical research programs. While some of the trial results have indeed been impressive, some of the results have been mixed. At a time when some may worry about a high rate of attrition, researchers have correctly pointed out that a high rate of attrition in phase I and II means that only the best trial drugs advance to phase III trials and beyond. In reviewing the cause of failure…
Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR discusses the current treatment landscape for high-risk multiple myeloma (MM) patients and what the next steps should be. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL. To see more videos go to http://www.vjhemonc.com/ Facebook: https://www.facebook.com/vjhemonc Twitter: https://twitter.com/VJHemOnc
Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ talks about new drugs being used for the treatment of multiple myeloma (MM), and where they fit in the current treatment landscape. He discusses how drugs like elotuzumab can be used in the early relapsed setting, whilst daratumumab is more suitbale for 3rd line therapy. He also talks about anit-CD38 therapies being used much earlier, perhaps even as front-line therapy or in combination with other drugs. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL. To see more videos go to http://www.vjhemonc.com/ Facebook: https://www.facebook.com/vjhemonc…
Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a Phase II clinical trial of ixazumib, the first oral proteosome inhibitor to be approved for the treatment of multiple myeloma (MM). The clinical trial assessed the effects and safety of different doses of ixazumib, which showed to have considerable single-agent activity in the MM setting. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL. To see more videos go to http://www.vjhemonc.com/ Facebook: https://www.facebook.com/vjhemonc Twitter: https://twitter.com/VJHemOnc
Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR provides an overview of the drugs recently approved for the treatment multiple myeloma (MM), and for which the data has been presented at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL. These include daratumumab, an anti-CD38 monoclonal antibody; ixazomib, the first oral proteasome inhibitor; and elotuzumab, a monoclonal antibody targeting signalling lymphocytic activation molecule F7 (SLAMF7).
Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA discusses the highlights of the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL. Dr Abramson focuses on the negative presented at ASH 2015, in particular the Pyramid clinical trial that assessed the addition of bortozemib to R-CHOP in diffuse large cell lymphoma (DLBCL), the CALGB-50403 study of bortozemib following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL), and the Lumiere trial of alisertib in relapsed/refractory peripheral T-cell lymphoma (PTCL).
Starting in February 2016, ADC Review / Journal of Antibody-drug Conjugates will offer select (video) interviews with KOLs (Key Opinion Leaders) and experts in the field of ADCs as well as Targeted and Personalized Medicine. This video is one of the intro/leaders used for our interview series. For more information about these interviews or inquiries about how to participate, please contact us at info@inpressmediagroup.com ADC Review / Journal of Antibody-drug Conjugates – http://www.adcreview.com © 2016 InPress Media Group, LLC
Fresh from the 2015 American Society of Hematology (ASH) conference, Dr. Michael Mauro of Memorial Sloan Kettering Cancer Center delves deeply into the world of CML, covering improved treatments and outcomes. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Where do we stand with CAR-T therapy? Could checkpoint inhibitors apply in CLL? CLL expert Dr. William Wierda, from the 2015 American Society of Hematology (ASH) meeting, shares his insights into this exploding field of research. Dr. Wierda explains developing immunotherapy options, including CAR T-cell therapies, which he feels hold the most hope as a curative strategy for CLL.CAR-T Cell Therapy is the next step to cure patients with CLL. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Myeloma expert Dr. Robert Orlowski answers more Ask the Expert questions, this one from Susan: What effect will newly approved drugs, such as daratumamab and ixazomib have on a patient when Revlimid maintenance is no longer effective? Dr. Orlowski gives a detailed answer, including a newer drug, isatuximab, that he says, looks like an active and exciting drug. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
At a recent MPN town meeting, MPN experts Dr. Srdan Verstovsek and Dr. Naval Daver from MD Anderson Cancer Center and Dr. Rami Komrokji from Moffitt Cancer discussed treatment considerations for myelofibrosis patients prior to stem cell transplant. Each of the experts shares their perspective on how genetic testing shapes treatment choices, how age affects the decision, and why or why not a particular patient makes a good candidate for transplant. Watch to learn more about why this is an individualized decision for each patient. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info…
Watch an in-depth discussion on emerging immunotherapy approaches for advanced prostate cancer with MD Anderson Cancer Center experts, Drs. Sumit Subudhi and Jeri Kim. Learn about treatments including experimental vaccine treatments and checkpoint inhibitors/immune modulators. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Francesco Annibale d’Amore, MD, PhD from Aarhus University, Aarhus, Denmark provides an overview of the LUMIERE clinical trial of alisertib (MLN8237), an Aurora A kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma. When compared to standard of care, such as romidepsin, pralatrexate and gemcitabine, there was no difference in terms of efficacy. However, Dr D’Amore discusses that this clinical was a great achievement in a field of rare diseases such as T-cell lymphomas.
Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA gives an overview of the preliminary data being presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL, on the results of a bromodomain and extra-terminal motif (BET) inhibitor for the treatment of non-Hodgkin lymphoma in a first in-human Phase I study.
Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase I study of ONO/GS-4059, a selective Bruton’s tyrosine kinase (BTK) inhibitor, in relapsed and refractory mature B-cell malignancies. Prof. Dyer presents the data showing the reduced toxicity of ONO/GS-4059 in comparison with the 1st generation BTK inhibitor ibrutinib.
Jacqueline Barrientos, MD, discusses the drug acalabrutinib (ACP-196), a second generation Bruton’s tirosine kinase (BTK) inhibitor that demonstrates reduced off-target effects. Dr Barrientos provides an overview of the Phase I study, where 965 of patients responded to treatment, including patients that have been through partial remission with lymphocytosis.
Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA gives an overview of the preliminary data being presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL, on the results of the multi-centre prospective Phase II study of Dose-Adjusted EPOCH-R for Burkitt Lymphoma.
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Andrés Cervantes, MD, PhD, from the University of Valencia, Valencia, Spain, discusses topics of his highlight session at the congress that summarised research highlights in the management of patients with ovarian cancer in 2015, including the treatment of relapsed ovarian cancer and optimisation of the use of poly(ADP-ribose) polymerase (PARP) inhibitors. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Atsushi Ohtsu, MD, PhD, from National Cancer Center, Kashiwa, Japan, reviews promising approaches for the treatment of patients with gastrointestinal cancer, including molecular targeted therapies and clinical studies of anti-PD-1 antibodies, such as pembrolizumab, for advanced gastric or gastroesophageal junction adenocarcinoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Andrés Cervantes, MD, PhD, from the University of Valencia, Valencia, Spain, explains the approach to case study sessions at the congress, which are guided by expert-reviewed and evidence-based ESMO guidelines and aim to promote the international exchange of expertise between Asian and European oncologists. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from The University of Chicago Medicine, Chicago, IL, discusses the clinical development of immune checkpoint inhibitors, including pembrolizumab, an anti-PD-1 antibody, and durvalumab, an anti-PD-L1 antibody, for the treatment of patients with head and neck cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Johan Vansteenkiste, MD, PhD, from University of Leuven, Leuven, Belgium, discusses subgroup analyses and patient-reported outcomes from CheckMate 057, a phase 3, randomised clinical trial that was designed to compare nivolumab, an antiPD-1 antibody, with docetaxel for the treatment of patients with advanced non-squamous non-small cell lung cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Johan Vansteenkiste, MD, PhD, from University of Leuven, Leuven, Belgium, discusses a phase 1b clinical trial that was designed to evaluate the safety and antitumour activity of durvalumab, an anti-PD-L1 antibody, combined with tremelimumab, a CTLA-4 antibody, for the treatment of patients with stage III or IV non-small cell lung cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from The University of Chicago Medicine, Chicago, IL, discusses the subgroup and biomarker analysis of LUX-H&N1, a phase 3 clinical trial comparing second-line afatinib, an ErbB family blocker, with methotrexate for the treatment of patients with recurrent and/or metastatic head and neck squamous cell carcinoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from The University of Chicago Medicine, Chicago, IL, discusses interim results from KEYNOTE-028, a phase 1b clinical trial that was designed to evaluate the antitumour activity and safety of pembrolizumab, an anti-PD-1 antibody, for the treatment of patients with PD-L1-positive nasopharyngeal carcinoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Fatima Cardoso, MD, from Champalimaud Cancer Centre, Lisbon, Portugal, discusses the implementation of ESMO guidelines on the treatment of metastatic HER2-positive breast cancer in a case study presentation, including the use of the antibody-drug conjugate, T-DM1, and the anti-HER2 antibody, pertuzumab, in different settings of treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Peter Hersey, MD, PhD, from the Melanoma Institute Australia, Sydney, Australia, discusses the opportunities and challenges of promising immunotherapeutic approaches for the treatment of patients with melanoma, including immune checkpoint inhibitors that target pathways related to T-cell activity. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ, provides an overview of the session “Social Media for the Hematologist” held at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. In this session, it was discussed how social media has become a part of medical practice, research, education, and the value of these tools and how to use them effectively.
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, ESMO and Congress President, Rolf A. Stahel, MD, from the University Hospital Zurich, Zurich, Switzerland, explains that the ESMO Asia Congress provides an opportunity for Asian and European oncologists to come together to promote an exchange of expertise, and highlights the access of new medicines as a global challenge. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, ESMO and Congress President, Rolf A. Stahel, MD, from the University Hospital Zurich, Zurich, Switzerland, provides an overview of approaches that aim to improve patient access to new cancer medicines, including the ESMO Magnitude of Clinical Benefit Scale, which is a validated approach to stratify the magnitude of clinical benefit for cancer medicines. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Martin Reck, MD, PhD, from LungenClinic Grosshansdorf, Grosshansdorf, Germany, discusses an evaluation of overall health status in patients with advanced squamous non-small cell lung cancer (NSCLC) treated with nivolumab, an anti-PD-1 antibody, or docetaxel in CheckMate 017; and subgroup analyses and patient reported outcomes in patients with advanced non-squamous NSCLC treated with nivolumab or docetaxel in CheckMate 057. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Recently, there have been numerous advances in the biological understanding of ovarian cancer. At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Jonathan A. Ledermann, BSc, MD, FRCP, from UCL Cancer Institute and UCL Hospitals, London UK, discusses the therapeutic development and impact of olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, for the management of patients with BRCA-related ovarian cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Karim Fizazi, MD, PhD, from Gustave Roussy, Villejuif, France, explains that recent developments in the treatment of castrate-resistant prostate cancer have improved overall survival for patients, and now, optimal sequencing of new treatment agents and approaches, such as abiraterone, enzalutamide, docetaxel, cabazitaxel, radium-223 and sipuleucel-T, is the next challenge. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Richard A. Van Etten, MD of UC Irvine Health Chao Family gives an update on Chronic Myeloid Leukemia using data from ASH at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach
Susan OBrien, MD of UC Irvine Health Chao Family gives an update of Chronic Lymphocytic Leukemia with data from ASH 2015 at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach
Kanwarpal S. Kahlon , MD of UC Irvine Health Chao Family gives an Update on Multiple Myeloma at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach
Deepa Jeyakumar, MD of UC Irvine Health Chao Family gives an update on Acute Myeloid Leukemia at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach
Angela Fleischman, MD, PhD of University of California, Irvine discusses Mutational Landscape of MPN; Emerging JAK Inhibitors; Ruxolitinib Combination Trials; Anti-Fibrotic Agents at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach
Monica El-Masry, MD & Bhavana Pathak, MD present Cardiovascular Disease in Adolescents and Young Adults with Hematologic Malignancies at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach
Eric Van Cutsem, MD of University of Leuven discusses the RECOURSE trial design and its primary endpoint results at ASCO Gi 2016
Eric Van Cutsem, MD of University of Leuven discusses the risk-benefit ratio for TAS-102 in advanced treatment refractory colorectal cancer at ASCO GI 2016